Peptonic Medical

 Message from our CEO

Important steps towards establishing a leading Swedish Femtech Company

We are continuing with quick steps to build the New Peptonic. Our vision is to build a leading company in the rapidly growing global market for women’s intimate care. We are developing a portfolio based on the principle: diagnose, treat, prevent where the user shall be able to manage her intimate health all the way from diagnose to treatment and preventive solutions with the company’s clinically proven self-care products. During the quarter possibly the most important step so far was taken by signing a letter of intent to merge with Swedish Pharmiva AB.

The Swedish Femtech company Pharmiva has developed a unique and patented self care product for the treatment of bacterial vaginosis. The product is a perfect addition to Peptonic’s self test for the same indication, VagiVital VS. The self test for bacterial vaginosis is the best selling product for Peptonic world wide where US is the market where we sell the most. To be able to offer a patented treatment next to the self test in these channels becomes a very strong offer. It will become the first medical condition where we distinctively will be able to put a diagnose, treat and prevent offer on the table. More is coming..

In addition to very strong product and portfolio synergies there are also great organizational synergies in a merger with Pharmiva. Ever since the launch in Sweden Pharmiva’s product Vernivia has grown very rapidly in the Swedish market. And already year one the company reached a 10% market share and was awarded the new comer of the year by the national pharma retail chain, Apotek Hjärtat.

Also Peptonic continues to deliver rapid growth in the Swedish market. During the quarter Peptonic’s VagiVital AktivGel was made available for sales in Apoteket Hjärtat’s physical stores. Furthermore,  Pharmiva and Peptonic have a similar approach to consumer marketing, and by merging the two companies a very strong sales and marketing team will be formed in the New Peptonic, which will further accelerate sales growth.

During the quarter Peptonic has also continued taking steps to strengthen the organization. In August Terese Torenfält will start as Partner Manager Europe and as of October Albert Lindgren will start as the company’s new CFO. Both Terese and Albert comes with solid and relevant experience in their respective fields, which bodes for accelerated expansion of the business in markets outside Nordics.

The Business Unit Lifestyle Consumer is again delivering growth both in comparison to previous quarter as well as in a comparison to the same period previous year. It is also very encouraging that Heli Kurjanen, General Manager of our subsidiary Lune in Finland, has been awarded the price for the Most Influential Menstrual Care Business Leader Nordics, 2023 by AI Global Media Ltd.

During the fall the focus will be to conclude the merger process with Pharmiva and to build a new much stronger organization enabling accelerated sales growth, geographical expansion, continuous portfolio development and route to profitability according to the set strategy. I look forward to updating you further on coming milestones for  the New Peptonic.

Erik Sundquist

CEO

FINANCIAL INFORMATION

Group

Revenue – Sales of goods during the second quarter amounted to SEK 11,930 (12,354) thousand. Other operating income for the quarter was SEK 190 (329) thousand. In the first half of the year, sales of goods amounted to SEK 20,804 (21,262) thousand. Other operating income for the half year was SEK 383(850) thousand. The core Medical Consumer business grew during the first half of the year. The Lifestyle Consumer business area declined, but had a much stronger second quarter. With the exception of two major orders to Orion in the first half of 2022, the company grew in comparison.

Costs – Costs for the second quarter amounted to SEK -19,497 (-20,829) thousand.

Costs of goods sold for the quarter amounted to SEK -5,716 (-6,085) thousand, which corresponds to a gross profit of SEK 6,214 (6,269) thousand and a gross margin of 52% (51%). During the half year, costs for products were SEK -9,721 (-9,397) thousand, which corresponds to a gross profit of SEK 11,084 (11,865) thousand and a gross margin of 53% (56%), where the difference is primarily in the product mix.

 
Profit – The group's result after net financial items for the second quarter amounted to SEK -7,458 (-9,043) thousand. For the half year, the corresponding result is -15,478 (-20,301) KSEK. The improved result is an effect of implemented organizational efficiencies with reduced costs for external consultants.

Financial position and liquidity – Cash and bank as of June 30, 2023, amounted to SEK 12,722 (9,836) thousand. During the six months, a stock build-up of approx. SEK 3,100 thousand was made.

Shareholders equity – The group's equity as of June 30, 2023 amounted to SEK 84,129 (62,416) thousand, which gives an solvency of 86 (67) percent.

Liabilities – The group's short-term liabilities amounted, as of June 30, 2023, to SEK 14,200 (30,471) thousand. Of which SEK 4,800 thousand refers to interest-bearing deferrals with the Tax Agency.

Organization – During the period, the average number of employees was 31 (31). At the end of the period, the number of employees amounted to 31 (31). During the period, investments corresponding to SEK 500,000 were taken for recruitment of CFO and International Partner Manager. These services will be commissioned in the second half of 2023 and enable faster acceleration.

Audit

This year-end report has not been subject to be reviewed by the company's auditors.

Assurance

The board and the managing director assure that the year-end report provides a fair overview of the company's operations, position and results.

FINANCIAL CALENDER

Quarterly report, 3                                                                                                   2023-10-24

Year-end report, 2023                                                                                        2024-02-23

Stockholm on 11 of august, 2023

Anders Blom, Chairmen of the Board  Daniel Rudeklint, Board member

Anna Stinger, Board member   Anders Norling, Board member

Tarek Shoeb, Board member

Erik Sundquist, CEO

For more information please contact:

Erik Sundquist, CEO PEPTONIC Medical AB. Phone: +46 722 499 043

Note: This document has been prepared in both Swedish and English. The Swedish version shall govern in case of differences between the two documents. The document contains certain statements about the Company’s operating environment and future performance. These statements should only be regarded as reflective of prevailing interpretations. No guarantees can be made that these statements are free from errors.